CandidPharm · Ningbo Candid Pharmaceutical Co., Ltd. · 宁波嘉安药业有限公司
CATEGORY B · CP-ORFO-02Intermediate

5-((S)-2,2-dimethyltetrahydro2H-pyran-4-yl)-1-((1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro1,2,4-oxadiazol-3-yl) cyclopropyl)-1H-indole-2- carboxylic acid

5-[(S)-2,2-二甲基四氢-2H-吡喃-4-基]-1-[(1S,2S)-2-甲基-1-(5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)环丙基]-1H-吲哚-2-甲酸
CAS Registry No.
2212021-83-3
Related API
Orforglipron
Molecular Weight
411.5
Product Type
Intermediate

Identification & Structure

Chemical structure of 5-((S)-2,2-dimethyltetrahydro2H-pyran-4-yl)-1-((1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro1,2,4-oxadiazol-3-yl) cyclopropyl)-1H-indole-2- carboxylic acid
2D Structure

C[C@H]1C[C@]1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)[C@H]5CCOC(C5)(C)C)C=C3C(=O)O

Product CodeCP-ORFO-02
Product TypeIntermediate
CAS Number2212021-83-3
Molecular FormulaC22H25N3O5
Molecular Weight411.5
IUPAC Name5-[(4S)-2,2-dimethyloxan-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carboxylic acid
SMILESC[C@H]1C[C@]1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)[C@H]5CCOC(C5)(C)C)C=C3C(=O)O
InChIKeyVWANSYGDVGYGTG-RGDDPNHNSA-N
PubChem CID141723212
Quality ParametersRequest current specification and available batch documentation

Related API

Listed in our catalog as an intermediate related to Orforglipron.

Specifications and available documentation are reviewed against your project requirements. Availability and lead time are confirmed for each enquiry, taking current stock and production schedules into account.

Direct Inquiries

Request a Quote & Documents

Tell us the quantity, specification and destination. We will reply by email with pricing, lead time and the documents available.

· We will reply by email
· Mutual NDA available on request

Documents on Request

Request current specification and available batch documentation. We will confirm which TDS, SDS, CoA and analytical materials can be shared for this product.

Patent Notice

Supply is reviewed against the destination, patent status and intended use. Products are not offered where the transaction would infringe valid patents or supplementary protection certificates. Where applicable, regulatory-development activities may fall within the Bolar exemption under Article 10(6) of EU Directive 2001/83/EC, as amended by Directive 2004/27/EC, or 35 U.S.C. § 271(e)(1). These provisions have specific conditions; research use alone does not establish an exemption. Buyers must confirm applicable requirements for their jurisdiction and project before ordering. Commercial supply in protected territories requires an applicable legal basis.